Apel­lis ex­pects EU to re­ject eye drug; Ter­ray teams up with Bris­tol My­ers; Van­dria rais­es $20M

Plus, news on In­duc­tive Bio, AbelZe­ta Phar­ma, GPCR Ther­a­peu­tics, Bridge Bio­ther­a­peu­tics and NextCure.

Apel­lis pre­empts EU re­jec­tion for eye drug: The com­pa­ny

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER